メニュー
世界の品質管理基準等に対応し、安心や安全をお届けします。
Delivering relibility and safety with global standards
各国の法令等を遵守し、商品やサービス等を適切に管理します。
Complying with laws and regulations of each country
高度な専門知識を備え、情報の収集提供に迅速に対応します。
Keeping up on the latest information and knowledge
医療現場の多種多様なニーズに的確に対応できるよう努めます。
Offering healthcare support for diverse market needs
常にグローバルな視点で捉え、社会貢献していくことを目指します。
Making a social contribution from a global viewpoint
最新のAI・通信技術を活用し、臨床検査サービスを提供します。
Harnessing newest AI and ITC for diagnostic services
企業の社会的責任を果たすためにCSR活動にも取り組みます。
Undertaking Corporate Social Responsibility activities
“We combine expertise, technology, safety, and patient care.”
“We combine expertise, technology, safety, and patient care.”
代表取締役社長 山田 哲児
取締役 伊原 昌義
取締役 India
執行役員 石原 義盛
監査役 井福 武志
顧問 小川 眞史
顧問 近藤 俊之
Accreditation is expected to become a requirement in the near future, making it essential for laboratories to achieve NABL accreditation. From this perspective, the business potential is promising, with approximately 98% of labs yet to attain NABL accreditation.
Japan has been a pioneer in rejuvenating stagnant economies through its innovations and advanced technologies. At J-VPL, we offer future-oriented Japanese technologies exclusively. Our business model is designed for consistency and sustainability, providing a unique opportunity to enter the healthcare diagnostics segment.
Accreditation is expected to become a requirement in the near future, making it essential for laboratories to achieve NABL accreditation. From this perspective, the business potential is promising, with approximately 98% of labs yet to attain NABL accreditation.
Japan has been a pioneer in rejuvenating stagnant economies through its innovations and advanced technologies. At J-VPL, we offer future-oriented Japanese technologies exclusively. Our business model is designed for consistency and sustainability, providing a unique opportunity to enter the healthcare diagnostics segment.
Accreditation is expected to become a requirement in the near future, making it essential for laboratories to achieve NABL accreditation. From this perspective, the business potential is promising, with approximately 98% of labs yet to attain NABL accreditation.
Japan has been a pioneer in rejuvenating stagnant economies through its innovations and advanced technologies. At J-VPL, we offer future-oriented Japanese technologies exclusively. Our business model is designed for consistency and sustainability, providing a unique opportunity to enter the healthcare diagnostics segment.
代表取締役社長 山田 哲児
取締役 伊原 昌義
取締役 India
執行役員 石原 義盛
監査役 井福 武志
顧問 小川 眞史
顧問 近藤 俊之
Three Year’s Plan
Uttar Pradesh
Rajasthan
Punjab
Meghalaya
Sikkim
Maharashtra
Bihar
West Bengal
Madhya Pradesh
Tamil Nadu
Gujarat
Kerala
Assam
Uttarakhand
Mizoram
Manipur
Odisha
Uttar Pradesh
Telangana
Jharkhand
Himachal Pradesh
Jammu & Kashmir
Haryana
Chhattisgarh
Andhra Pradesh
Bihar
Maharastra
Tamil Nadu
Madhya Pradesh
Karnataka
Rajasthan
PGI Chandigarh
Meghalaya
Mizoram
We are expanding our network of Onco Pathology Laboratories across India, with a vision to make high-precision cancer diagnostics accessible to a wider population.
The healthcare industry’s future, as foreseen by industry experts and global research organizations, revolves around genetics and cutting-edge technologies. Join us in our investor relations to access upcoming, life-changing opportunities that not only contribute to society’s well-being but also offer revenue potential. It’s the right time to invest in the right industry and products.
Accreditation is expected to become a requirement in the near future, making it essential for laboratories to achieve NABL accreditation. From this perspective, the business potential is promising, with approximately 98% of labs yet to attain NABL accreditation.
Japan has been a pioneer in rejuvenating stagnant economies through its innovations and advanced technologies. At J-VPL, we offer future-oriented Japanese technologies exclusively. Our business model is designed for consistency and sustainability, providing a unique opportunity to enter the healthcare diagnostics segment.
Uttar Pradesh
Rajasthan
J-VPL Advance Anatomic and Molecular Pathology Pvt Ltd
2nd Floor , NBCC Center, Plot No. 2, Community Center, Okhla Phase I, New Delhi, Delhi 110020
Sikkim
Maharashtra
Bihar
West Bengal
Madhya Pradesh
Tamil Nadu
Gujarat
Kerala
Assam
Uttarakhand
Mizoram
Manipur
Odisha
Uttar Pradesh
Telangana
Jharkhand
Himachal Pradesh
Jammu & Kashmir
Haryana
Chhattisgarh
Andhra Pradesh
Bihar
Maharastra
Tamil Nadu
Madhya Pradesh
Karnataka
Rajasthan
J-VPL Advance Anatomic and Molecular Pathology
PGI Chandigarh
Meghalaya
Punjab
We are expanding our network of Onco Pathology Laboratories across India, with a vision to make high-precision cancer diagnostics accessible to a wider population.
◆臨床検査受託業
◆検査キット開発及び製造・販売
◆検査試薬開発及び製造・販売
◆医薬部内外品の販売及び輸出入
◆メディカル物流事業
◆代替医療
◆中古医療機器販売及び賃貸業
◆医療経営コンサルティング業務
◆医療関連企業向けのマーケティング
◆J-VPD東京ラボラトリー
東京都新宿区愛住町23-14 ベルックス新宿ビル 6階
◆J-VPD研究所
東京都新宿区愛住町23-14 ベルックス新宿ビル 6階
◆J-VPD Diagnostics India Pvt. Ltd.(インド現地法人)
A-415, Lower Ground Floor, Defence Colony, New Delhi South Delhi DL 110024
Mobile No:- 8630834830
◆J-VPL Advance Anatomic And Molecular Pathalogy Pvt. Ltd.
◆株式会社ディ・シー・オー
東京都新宿区愛住町23-14 ベルックス新宿ビル 6階
“We combine expertise, technology, safety, and patient care.”
“We combine expertise, technology, safety, and patient care.”
“We combine expertise, technology, safety, and patient care.”
“We combine expertise, technology, safety, and patient care.”
東京都新宿区愛住町23-14
ベルックス新宿ビル 6階
月-金：9:00~18:00、土：10:00~18:00
日、祝日：定休日
東京都新宿区愛住町23-2
ベルックス新宿ビルⅡ 8階
月-金：9:00~18:00、土：10:00~18:00
日、祝日：定休日
東京都新宿区愛住町23-2
ベルックス新宿ビルⅡ 8階
月-金：9:00~18:00、土：10:00~18:00
日、祝日：定休日
東京都新宿区愛住町23-2
ベルックス新宿ビルⅡ 8階
月-金：9:00~18:00、土：10:00~18:00
日、祝日：定休日
月-金：9:00~18:00、土：10:00~18:00
日、祝日：定休日
